Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00620607 (CLINICAL TRIAL / IMGN242 / HUC242-DM4)

Study Title 
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas (NCT00620607)

Trial Description
To assess the response rate of huC242-DM4 (also known as IMGN242) given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.

This trial is sponsored by ImmunoGen, Inc. [1]

Study Data

  • Condition:
  • Interventions:
    • Drugs used in this trial
      • huC242-DM4 (IMGN242 )
  • Phase: II
  • Estimated Enrollment: 45
  • Start: May 2007
  • Estimated Completion: September 2010
  • Last verified: April 2009

Study Schematic 

(Coming soon)


Last Editorial review: September 29, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar